2-benzylidene-7-((4-methoxybenzyl)oxy)-2,3-dihydro-1H-inden-1-one | 1296835-86-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-benzylidene-7-((4-methoxybenzyl)oxy)-2,3-dihydro-1H-inden-1-one
• 英文别名: 2-benzylidene-7-(4-methoxybenzyloxy)indan-1-one；2-Benzylidene-7-(4-methoxy-benzyloxy)-indan-1-one；2-benzylidene-7-[(4-methoxyphenyl)methoxy]-3H-inden-1-one
• CAS: 1296835-86-3
• 化学式: C₂₄H₂₀O₃
• 分子量: 356.421
• InChiKey: VGTNLXYNUWQLFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-benzylidene-7-((4-methoxybenzyl)oxy)-2,3-dihydro-1H-inden-1-one 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以70%的产率得到2-benzylidene-7-hydroxy-2,3-dihydro-1H-inden-1-one
  参考文献：
  名称：

  Identification of novel 2-benzyl-1-indanone analogs as interleukin-5 inhibitors

  摘要：

  A novel series of 2-benzyl-1-indanone analogs were investigated as IL-5 inhibitory activity. Among the synthesized compounds, 7-(cyclohexylmethoxy)-2-(4-hydroxybenzy1)-2,3-dihydro-1H-inden-l-one (7s, 100.0% inhibition at 30 mu M, IC50 = 4.0 mu M), and 7-(cyclohexylmethoxy)-2-(3-hydroxybenzyl)-2,3-dihydro-1H-inden-1-one (7t, 95.0% inhibition at 30 mu M, IC50 = 6.0 mu M) showed the best inhibitory activity against IL-5. The 2-benzyl-1-indanone analogs showed moderate to strong IL-5 inhibitory activity. Especially, hydroxyl (HBD/HBA) substituent at position 3 or 4 on phenyl ring B showed potent IL-5 inhibition. Additionally, the bulky hydrophobic cyclohexylmethoxy group at position 7 of the 1-indanone ring is favorable for the inhibitory activity. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.04.030
• 作为产物：
  描述：

  苯酚 在 potassium carbonate 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 2-benzylidene-7-((4-methoxybenzyl)oxy)-2,3-dihydro-1H-inden-1-one
  参考文献：
  名称：

  Identification of novel 2-benzyl-1-indanone analogs as interleukin-5 inhibitors

  摘要：

  A novel series of 2-benzyl-1-indanone analogs were investigated as IL-5 inhibitory activity. Among the synthesized compounds, 7-(cyclohexylmethoxy)-2-(4-hydroxybenzy1)-2,3-dihydro-1H-inden-l-one (7s, 100.0% inhibition at 30 mu M, IC50 = 4.0 mu M), and 7-(cyclohexylmethoxy)-2-(3-hydroxybenzyl)-2,3-dihydro-1H-inden-1-one (7t, 95.0% inhibition at 30 mu M, IC50 = 6.0 mu M) showed the best inhibitory activity against IL-5. The 2-benzyl-1-indanone analogs showed moderate to strong IL-5 inhibitory activity. Especially, hydroxyl (HBD/HBA) substituent at position 3 or 4 on phenyl ring B showed potent IL-5 inhibition. Additionally, the bulky hydrophobic cyclohexylmethoxy group at position 7 of the 1-indanone ring is favorable for the inhibitory activity. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.04.030

文献信息

• HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：JACKSON Paul F.

  公开号：US20110105494A1

  公开（公告）日：2011-05-05

  This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R 2 , R 3 , and R 4 are as defined in the specification.

  这项发明涉及一种新型芳基吲哚嘧啶A及其治疗和预防用途。治疗和/或预防的疾病包括帕金森病。其中X、R2、R3和R4如规范中定义。
• HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
  申请人：JACKSON Paul F.

  公开号：US20110105493A1

  公开（公告）日：2011-05-05

  This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R 2 , R 3 , and R 4 are as defined in the specification.

  这项发明涉及一种新的芳基吲哚吡啶，A，以及其治疗和预防用途。治疗和/或预防的疾病包括帕金森病。其中X，R2，R3和R4如规范中定义。
• 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
  申请人：JACKSON Paul F.

  公开号：US20110105540A1

  公开（公告）日：2011-05-05

  This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease.

  本发明涉及一种新型芳基茚嘧啶A及其治疗和预防用途。所治疗和/或预防的疾病包括帕金森病。